Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zai Lab (ZLAB) Non-Current Deffered Revenue (2021 - 2025)

Zai Lab's Non-Current Deffered Revenue history spans 5 years, with the latest figure at $27.3 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 13.04% year-over-year to $27.3 million; the TTM value through Dec 2025 reached $27.3 million, down 13.04%, while the annual FY2025 figure was $27.3 million, 13.04% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $27.3 million at Zai Lab, down from $28.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $31.4 million in Q4 2024 and bottomed at $21.4 million in Q4 2022.
  • The 5-year median for Non-Current Deffered Revenue is $27.6 million (2021), against an average of $27.2 million.
  • The largest annual shift saw Non-Current Deffered Revenue decreased 22.29% in 2022 before it soared 34.54% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $27.5 million in 2021, then fell by 22.29% to $21.4 million in 2022, then skyrocketed by 34.54% to $28.7 million in 2023, then increased by 9.38% to $31.4 million in 2024, then fell by 13.04% to $27.3 million in 2025.
  • Per Business Quant, the three most recent readings for ZLAB's Non-Current Deffered Revenue are $27.3 million (Q4 2025), $28.1 million (Q3 2025), and $29.2 million (Q2 2025).